Eisenhauer, E. A., Abdihamid, O., Booth, C. M., Cherny, N., Fojo, A. T., Gyawali, B., Marini, B. L., Mohyuddin, G. R., Pe, M., Pond, G. R., Soto-Perez-de-Celis, E., Tannock, I. F., Trapani, D., Tregear, M., van der Graaf, W. T. A., & Wilson, B. E. (2025). Guidance for discussants of randomized cancer trials at major meetings. European Journal of Cancer, 220, 115357. https://doi.org/10.1016/j.ejca.2025.115357

Dimitriou, F., Orloff, M. M., Koch Hein, E. C., Cheng, P. F., Hughes, I. F., Simeone, E., Montazeri, K., Grover, P., Mehmi, I., Gerard, C. L., Gaudy-Marqueste, C., Grob, J.-J., Michielin, O., Hamid, O., Long, G. V., Sullivan, R., Kapiteijn, E., Johnson, D. B., Ascierto, P. A., … Dummer, R. (2025). Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors. European Journal of Cancer, 214, 115161. https://doi.org/10.1016/j.ejca.2024.115161

Matsuo, K., Chen, L., Neuman, M. K., Klar, M., Roman, L. D., & Wright, J. D. (2024). Low-grade endometrioid endometrial cancer with adnexal only metastasis: Evaluation of de-escalation of adjuvant therapy. European Journal of Cancer, 113533. https://doi.org/10.1016/j.ejca.2024.113533

Chung, R., McKiernan, J., Arpaia, N., Marabelle, A., & Rouanne, M. (2023). Neo-Adjuvant immunotherapies: Bladder cancer as a platform for drug development targeting mucosal immunity. European Journal of Cancer, 187, 58–64. https://doi.org/10.1016/j.ejca.2023.03.037

Miholjcic, T. B. S., Halse, H., Bonvalet, M., Bigorgne, A., Rouanne, M., Dercle, L., Shankar, V., & Marabelle, A. (2023). Rationale for LDH-targeted cancer immunotherapy. European Journal of Cancer, 181, 166–178. https://doi.org/10.1016/j.ejca.2022.11.032

Loibl, S., Loirat, D., Tolaney, S. M., Punie, K., Oliveira, M., Rugo, H. S., Bardia, A., Hurvitz, S. A., Brufsky, A. M., Kalinsky, K., Cortés, J., O’Shaughnessy, J. A., Dieras, V., Carey, L. A., Gianni, L., Gharaibeh, M., Preger, L., Phan, S., Chang, L., … Piccart, M. J. (2023). Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. European Journal of Cancer, 178, 23–33. https://doi.org/10.1016/j.ejca.2022.10.003

Dercle, L., Ammari, S., Roblin, E., Bigorgne, A., Champiat, S., Taihi, L., Plaian, A., Hans, S., Lakiss, S., Tselikas, L., Rouanne, M., Deutsch, E., Schwartz, L. H., Gönen, M., Flynn, J., Massard, C., Soria, J.-C., Robert, C., & Marabelle, A. (2022). High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy. European Journal of Cancer, 177, 80–93. https://doi.org/10.1016/j.ejca.2022.08.034

Rosenbaum, E., Chugh, R., Ryan, C. W., Agulnik, M., Milhem, M. M., George, S., Jones, R. L., Chmielowski, B., Van Tine, B. A., Tawbi, H., Elias, A. D., Read, W. L., Budd, G. T., Qin, L.-X., Rodler, E. T., Hirman, J., Weiden, P., Bennett, C. M., Livingston, P. O., … Carvajal, R. D. (2022). A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. European Journal of Cancer, 176, 155–163. https://doi.org/10.1016/j.ejca.2022.09.003

Fontana, E., Williams, A., Falchook, G., Lakhani, N., Evans, T. R. J., Gondi, V., Iwamoto, F., McKean, M., Symeonides, S., Butowski, N., McLaren, A., Henry, J., Buerki, R., Rotolo, J., Capiaux, G., Michel, R., Kaesshaefer, S., Wiegert, E., & Bexon, A. (2022). Efficacy signals, long-term exposure and safety data from a phase 1–2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients (pts) with refractory solid tumors. European Journal of Cancer, 174, S82–S83. https://doi.org/10.1016/s0959-8049(22)01018-8

Chen, Z., Tang, X., Christin, J. R., Gao, S. P., Chu, C. E., Berger, M. F., Schultz, N. D., Shen, M. M., Al-Ahmadie, H. A., Iyer, G., Kim, K., & Solit, D. B. (2022). HER2 as a therapeutic target in bladder cancer. European Journal of Cancer, 174, S10–S11. https://doi.org/10.1016/s0959-8049(22)00829-2

Macy, M., Cash, T., Pinto, N., Pressey, J. G., Szalontay, L., Furman, W. L., Bukowinski, A., Foster, J. H., Friedman, G. K., HaDuong, J., Fox, E., Weigel, B. J., Grevel, J., Huang, F., Phelps, C., Childs, B. H., Chung, J., Chaturvedi, S., Schulz, A., & DuBois, S. G. (2022). Phase I dose-escalation study of the pan-PI3 K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors. European Journal of Cancer, 174, S28–S29. https://doi.org/10.1016/s0959-8049(22)00878-4

Dinia, A., Ammari, S., Filtes, J., Classe, M., Moya-Plana, A., Bidault, F., Temam, S., Blanchard, P., Lassau, N., & Gorphe, P. (2022). Events prediction after treatment in HPV-driven oropharyngeal carcinoma using machine learning. European Journal of Cancer, 171, 106–113. https://doi.org/10.1016/j.ejca.2022.05.003

Maniar, A., Haslam, A., & Prasad, V. (2022). Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours. European Journal of Cancer, 164, 95–104. https://doi.org/10.1016/j.ejca.2022.01.006

Dercle, L., Zhao, B., Gönen, M., Moskowitz, C. S., Connors, D. E., Yang, H., Lu, L., Reidy-Lagunes, D., Fojo, T., Karovic, S., Maitland, M. L., Oxnard, G. R., & Schwartz, L. H. (2022). An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scans. European Journal of Cancer, 161, 138–147. https://doi.org/10.1016/j.ejca.2021.10.029

Vogl, U. M., Beer, T. M., Davis, I. D., Shore, N. D., Sweeney, C. J., Ost, P., Attard, G., Bossi, A., de Bono, J., Drake, C. G., Efstathiou, E., Fanti, S., Fizazi, K., Halabi, S., James, N., Mottet, N., Padhani, A. R., Roach, M., Rubin, M., … Gillessen, S. (2022). Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. European Journal of Cancer, 160, 24–60. https://doi.org/10.1016/j.ejca.2021.09.036